10x Genomics, Inc. (TXG) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
33.91
↑+117% vs avg
5yr avg: 15.64
30Y Low15.6·High15.6
P/B Ratio
↓
5.44
↓-30% vs avg
5yr avg: 7.82
30Y Low2.4·High20.1
ROE
↑
-5.8%
↓+69% vs avg
5yr avg: -18.4%
30Y Low-94%·High-6%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TXG Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
10x Genomics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 33.9x P/FCF, 117% above the 5-year average of 15.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.4B | $2.0B | $1.7B | $6.6B | $4.1B | $16.4B | $14.3B | $3.0B | — | — |
| Enterprise Value | $4.1B | $1.7B | $1.5B | $6.3B | $4.0B | $15.9B | $13.7B | $2.6B | — | — |
| P/E Ratio → | -99.30 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.86 | 3.17 | 2.83 | 10.60 | 8.03 | 33.51 | 47.93 | 12.12 | — | — |
| P/B Ratio | 5.44 | 2.56 | 2.44 | 8.85 | 5.15 | 20.11 | 19.38 | 7.10 | — | — |
| P/FCF | 33.91 | 15.64 | — | — | — | — | — | — | — | — |
| P/OCF | 32.43 | 14.96 | 259.56 | — | — | — | — | 86.08 | — | — |
P/E links to full P/E history page with 30-year chart
TXG EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.67 | 2.40 | 10.17 | 7.79 | 32.48 | 45.92 | 10.52 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 13.21 | — | — | — | — | — | — | — | — |
TXG Profitability
Margins and return-on-capital ratios measuring operating efficiency
10x Genomics, Inc. earns an operating margin of -17.2%. Operating margins have expanded from -42.9% to -17.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -5.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.1% | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% | 80.4% | 75.2% | 80.4% | 85.1% |
| Operating Margin | -17.2% | -17.2% | -31.9% | -42.9% | -32.5% | -10.8% | -28.6% | -11.8% | -75.7% | -25.8% |
| Net Profit Margin | -6.8% | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | -181.6% | -12.7% | -76.9% | -26.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.8% | -5.8% | -25.2% | -33.0% | -20.5% | -7.5% | -93.6% | -31.2% | — | — |
| ROA | -4.4% | -4.4% | -19.4% | -25.6% | -16.2% | -6.0% | -70.7% | -8.6% | -112.5% | -24.8% |
| ROIC | -17.9% | -17.9% | -31.5% | -34.4% | -25.4% | -17.6% | -78.0% | -85.0% | — | — |
| ROCE | -13.1% | -13.1% | -23.7% | -30.6% | -18.6% | -6.2% | -12.6% | -9.2% | -152.3% | -34.4% |
TXG Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $474M exceeds total debt of $158M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.12 | 0.13 | 0.12 | 0.10 | 0.09 | 0.07 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.40 | -0.37 | -0.36 | -0.15 | -0.62 | -0.81 | -0.94 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.43 | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -44424.00 | -7537.27 | -339.28 | -61.03 | -316.76 | -9.08 | -45.66 | -22.11 |
Net cash position: cash ($474M) exceeds total debt ($158M)
TXG Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
10x Genomics, Inc.'s current ratio of 4.46x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.09x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 4.69x to 4.46x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.46 | 4.46 | 4.97 | 4.69 | 4.85 | 6.77 | 6.56 | 7.63 | 3.28 | 3.08 |
| Quick Ratio | 4.09 | 4.09 | 4.26 | 4.11 | 4.23 | 6.23 | 6.30 | 7.38 | 3.02 | 2.86 |
| Cash Ratio | 3.41 | 3.41 | 3.34 | 3.06 | 3.28 | 5.32 | 5.62 | 6.73 | 2.01 | 2.16 |
| Asset Turnover | — | 0.62 | 0.66 | 0.64 | 0.50 | 0.48 | 0.32 | 0.41 | 1.18 | 0.94 |
| Inventory Turnover | 3.53 | 3.53 | 2.36 | 2.84 | 1.47 | 1.24 | 1.95 | 4.00 | 3.34 | 2.18 |
| Days Sales Outstanding | — | 46.84 | 52.51 | 67.74 | 73.66 | 63.44 | 62.54 | 49.54 | 70.07 | 68.50 |
TXG Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
10x Genomics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 2.9% | 6.4% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $125M | $120M | $117M | $114M | $110M | $101M | $39M | $13M | $12M |
Peer Comparison
Compare TXG with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TXGYou | $4B | -99.3 | — | 33.9 | 69.1% | -17.2% | -5.8% | -17.9% | — |
 PACB | $435M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 BRKR | $9B | -381.5 | 22.9 | 201.2 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 FLGT | $535M | -9.1 | — | — | 40.6% | -28.2% | -5.4% | -6.4% | — |
 CDNA | $1B | -65.5 | — | 37.4 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 RXRX | $1B | -2.2 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — |
 SEER | $96M | -1.4 | — | — | 11.8% | -486.7% | -25.1% | -21.5% | — |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $125B | 35.2 | 18.4 | 23.8 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
TXG — Frequently Asked Questions
Quick answers to the most common questions about buying TXG stock.
What is 10x Genomics, Inc.'s P/E ratio?
10x Genomics, Inc.'s current P/E ratio is -99.3x. This places it at the 50th percentile of its historical range.
What is 10x Genomics, Inc.'s ROE?
10x Genomics, Inc.'s return on equity (ROE) is -5.8%. The historical average is -31.0%.
Is TXG stock overvalued?
Based on historical data, 10x Genomics, Inc. is trading at a P/E of -99.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are 10x Genomics, Inc.'s profit margins?
10x Genomics, Inc. has 69.1% gross margin and -17.2% operating margin.